Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19505191 | 0.76 | — | — | |
| SCHEMBL8435940 | 0.62 | GBA1 (0.47) | KDM4EPOLBALOX15ALDH1A1GAA | |
| SCHEMBL6233396 | 0.61 | KDM4E (0.36) | KDM4EPOLBALOX15ALDH1A1GAA | |
| SCHEMBL17962638 | 0.58 | KDM4E (0.41) | KDM4EPOLBALOX15ALDH1A1GAA | |
| SCHEMBL8724995 | 0.58 | — | — | |
| SCHEMBL18927984 | 0.58 | GBA1 (0.39) | KDM4EPOLBALOX15ALDH1A1GAA | |
| SCHEMBL5865950 | 0.57 | GAA (0.49) | KDM4EALDH1A1GAA | |
| SCHEMBL19014188 | 0.57 | — | — | |
| SCHEMBL8560826 | 0.56 | DHFR (0.31) | KDM4EALDH1A1GAA | |
| SCHEMBL24684880 | 0.56 | GAA (0.38) | KDM4EPOLBALOX15GAAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | KDM4E 4494/4885POLB 1649/4885ALOX15 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.